Jack A. Khattar sold $293k of SUPN
President, CEO at SUPERNUS PHARMACEUTICALS, INC.. 6,322 shares at an average of $46.29, traded Sep 8, 2025, filed Sep 9, 2025.
Score components
- +25RoleCEO
- +14Trade size$293k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.6%, 3m -1.3%, 6m +16.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001539937-25-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2025 | MOption exercise Common Stock10b5-1 | +8,074 | $25.30 | $204k | 1,118,305 | Sep 9, 2025 |
| Sep 8, 2025 | SOpen-market sale Common Stock10b5-1 | -6,322 | $46.29 | $293k | 1,111,983 | Sep 9, 2025 |
| Sep 8, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -8,074 | $0.00 | $0 | 162,500 | Sep 9, 2025 |
Related signals
Other insiders at SUPERNUS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | SUPERNUS PHARMACEUTICALS, INC. | Padmanabh P. Bhatt Sr. VP of IP, CSO | $5.4M 107,250 shares | -160% | |
| 43Moderate | SUPERNUS PHARMACEUTICALS, INC. | Frederick M. Hudson director | $272k 5,369 shares | -8% | |
| 45Moderate | SUPERNUS PHARMACEUTICALS, INC. | Jack A. Khattar President, CEO | $1.8M 35,000 shares | -4% | |
| 53Moderate | SUPERNUS PHARMACEUTICALS, INC. | William Todd Horich SVP, Commercial Operations | $484k 8,877 shares | -100% | |
| 24Weak | SUPERNUS PHARMACEUTICALS, INC. | Frank Mottola SVP, Chief Tech. Ops. Officer | $87k 1,623 shares | -8% | |
| 50Moderate | SUPERNUS PHARMACEUTICALS, INC. | Georges Gemayel director | $1.0M 18,787 shares | -49% | |
| 21Weak | SUPERNUS PHARMACEUTICALS, INC. | Bethany Sensenig director | $228k 4,475 shares | -100% | |
| 33Weak | SUPERNUS PHARMACEUTICALS, INC. | Frank Mottola SVP, Chief Tech. Ops. Officer | $1.0M 20,000 shares | -98% | |
| 13Weak | SUPERNUS PHARMACEUTICALS, INC. | Padmanabh P. Bhatt Sr. VP of IP, CSO | $32k 710 shares | -5% | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | Jack A. Khattar President, CEO | $3.0M 59,900 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.